Real-world incidence and outcomes of immune-related adverse events in NSCLC patients

被引：1
|
作者：
Knox, A. [1 ]
Cloney, T. [1 ]
Janssen, H. [1 ]
Solomon, B. [1 ]
Alexander, M. [2 ]
John, T. [1 ]
机构：
[1] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
[2] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic, Australia
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.629
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
551P
引用
收藏
页码：S1684 / S1684
页数：1
相关论文
共 50 条
  • [31] Management of immune-related adverse events: A single-center retrospective analysis in a real-world scenario.
    Iacono, Donatella
    Vitale, Maria Grazia
    Cortiula, Francesco
    Macerelli, Marianna
    Cinausero, Marika
    Minisini, Alessandro Marco
    Valent, Francesca
    Tullio, Annarita
    Palmero, Lorenza
    Targato, Giada
    Zara, Diego
    Fasola, Gianpiero
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Improved Outcomes for Patients Developing Any Immune-Related Adverse Events in Advanced NSCLC Treated With Pembrolizumab Monotherapy
    Lee, A.
    Girling, B.
    Patel, G.
    Sawhney, P.
    Luong, M.
    Ohana, D.
    Forster, M.
    Lee, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S925 - S926
  • [33] Patterns and risk factors of immune-related adverse events in a real-world cohort with lung cancer receiving immunotherapy
    Hu, Xiao
    Gurinovich, Anastasia
    Pan, Stacey
    Salei, Yana
    Lin, Jeffrey
    Parsons, Susan K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Immune-related Adverse Events in Cancer Patients
    Pallin, Daniel J.
    Baugh, Christopher W.
    Postow, Michael A.
    Caterino, Jeffrey M.
    Erickson, Timothy B.
    Lyman, Gary H.
    ACADEMIC EMERGENCY MEDICINE, 2018, 25 (07) : 819 - 827
  • [35] Treatment Outcomes of Immune-Related Cutaneous Adverse Events
    Phillips, Gregory S.
    Wu, Jennifer
    Hellmann, Matthew D.
    Postow, Michael A.
    Rizvi, Naiyer A.
    Freites-Martinez, Azael
    Chan, Donald
    Dusza, Stephen
    Motzer, Robert J.
    Rosenberg, Jonathan E.
    Callahan, Margaret K.
    Chapman, Paul B.
    Geskin, Larisa
    Lopez, Adriana T.
    Reed, Vanessa A.
    Fabbrocini, Gabriella
    Annunziata, Maria Carmela
    Kukoyi, Oluwaseun
    Pabani, Aliyah
    Yang, Chih-Hsun
    Chung, Wen-Hung
    Markova, Alina
    Lacouture, Mario E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2746 - +
  • [36] Immune-related toxicities in NSCLC: Real-world experience from a tertiary cancer center
    d'Arienzo, P. D.
    Olsson-Brown, A. C.
    Sallam, M.
    Ortega-Franco, A.
    Wong, H.
    Escriu, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study
    Liu, Wenhui
    Ma, Fang
    Sun, Bao
    Liu, Yiping
    Tang, Haoneng
    Luo, Jianquan
    Chen, Huiqing
    Luo, Zhiying
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [38] Immune-related adverse events associated with checkpoint inhibitors therapy in a real world setting
    Amaral, Teresa
    Eigentler, Thomas
    Caballero, Paloma
    Tampouri, Ioanna
    Lomberg, Diana
    Assi, Zeinab
    Thomas, Ioannis
    Koechel, Ansgar
    Mueller, Alisa
    Kofler, Lukas
    Leiter, Ulrike
    Forschner, Andrea
    Garbe, Claus
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17
  • [39] Real-World Characterization of Immune-Related Adverse Events in Nova Scotia Patients Treated with Pembrolizumab or Durvalumab and Adherence to Toxicity Management Guidelines
    Bowles, S.
    Daniels, A.
    DiCostanzo, T.
    Minard, L.
    Scott, S.
    Snow, S.
    Teimouri, A.
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2024, 77 (02):
  • [40] Rechallenging with PD-1 Inhibitors: Incidence and Management of Immune-Related Adverse Events in Metastatic NSCLC
    Hoang, T.
    Elliot, M. J.
    Poletes, C.
    Corke, L.
    Weiss, J.
    Tsao, M. -S.
    Bradbury, P.
    Shepherd, F. A.
    Liu, G.
    Leighl, N.
    Sacher, A.
    Lau, S. C. M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S372 - S372
12345